Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard I Scher

Showing results (21-30 of 393) with videos related to

Pageof 40
Sort By:
European Urology|September 5, 2016
Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on DefinitionsEmmanuel S Antonarakis, Howard I Scher
Expert Review of Anticancer Therapy|August 14, 2018
Apalutamide for the treatment of prostate cancerDana E Rathkopf, Howard I Scher
Nature Reviews. Clinical Oncology|November 11, 2015
CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancersMin Yuen Teo, Howard I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2009
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancerKaren E Knudsen, Howard I Scher
British Journal of Cancer|October 23, 2018
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)Min Yuen Teo, Howard I Scher
The Oncologist|April 17, 2003
Clinical approaches to osseous metastases in prostate cancerMichael J Morris, Howard I Scher
Critical Reviews in Oncology/Hematology|July 10, 2003
Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer CenterMichael J Morris, Howard I Scher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axisHoward I Scher, Charles L Sawyers
JAMA Oncology|March 2, 2023
Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer-Calling Out the "Double Standard"Deaglan J McHugh, Howard I Scher
Urologic Oncology|March 31, 2015
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapyGabriel P Haas, Howard I Scher
Pageof 40

Showing results (21-30 of 393) with videos related to

Sort By:
Pageof 40
European Urology|September 5, 2016
Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on DefinitionsEmmanuel S Antonarakis, Howard I Scher
Expert Review of Anticancer Therapy|August 14, 2018
Apalutamide for the treatment of prostate cancerDana E Rathkopf, Howard I Scher
Nature Reviews. Clinical Oncology|November 11, 2015
CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancersMin Yuen Teo, Howard I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2009
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancerKaren E Knudsen, Howard I Scher
British Journal of Cancer|October 23, 2018
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)Min Yuen Teo, Howard I Scher
The Oncologist|April 17, 2003
Clinical approaches to osseous metastases in prostate cancerMichael J Morris, Howard I Scher
Critical Reviews in Oncology/Hematology|July 10, 2003
Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer CenterMichael J Morris, Howard I Scher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axisHoward I Scher, Charles L Sawyers
JAMA Oncology|March 2, 2023
Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer-Calling Out the "Double Standard"Deaglan J McHugh, Howard I Scher
Urologic Oncology|March 31, 2015
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapyGabriel P Haas, Howard I Scher
Pageof 40